1
|
Yagi M, Nagata K, Sano M, Yanagihara K, Ohashi R, Takei H. Impact of IMP3 Expression on Chemotherapy Response and Prognosis in Triple-Negative Breast Cancer: A Retrospective Cohort Study. J NIPPON MED SCH 2025; 92:44-51. [PMID: 40058835 DOI: 10.1272/jnms.jnms.2025_92-109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/13/2025]
Abstract
BACKGROUND Although advances in neoadjuvant chemotherapy (NAC) are improving the rate of pathological complete response (pCR) and outcomes for triple-negative breast cancer (TNBC) patients, the prognosis remains poor. Insulin-like growth factor II mRNA-binding protein 3 (IMP3) expression was recently reported to be associated with chemotherapy resistance and poor prognosis in TNBC. METHODS We evaluated IMP3 expression in 40 female TNBC patients to assess its association with NAC sensitivity and outcome. RESULTS Among the cohort, 11 patients (27.5%) had IMP3-positive TNBC, which was associated with a higher Ki-67 labeling index (p = 0.119), indicating greater malignancy. However, IMP3 positivity showed no significant correlation with NAC resistance or differences in disease-free survival (DFS) as compared with IMP3-negative patients. CONCLUSIONS Patients receiving effective immunotherapy or high-dose chemotherapy achieved pCR regardless of IMP3 status, which suggests that the NAC regimen is more important than IMP3 status for pCR. Even in IMP3-positive TNBC, NAC may improve prognosis by achieving pCR. Thus, while IMP3 might predict poor prognosis, it may not serve as a definitive marker in the context of NAC. Because IMP3 is involved in cancer stem cell (CSC) function, further research is necessary to understand its complex role in CSCs and TNBC.
Collapse
Affiliation(s)
- Mio Yagi
- Department of Breast Surgery and Oncology, Nippon Medical School Tama Nagayama Hospital
| | - Koji Nagata
- Department of Diagnostic Pathology, Nippon Medical School Tama Nagayama Hospital
| | - Megumi Sano
- Department of Breast Surgery and Oncology, Nippon Medical School Tama Nagayama Hospital
| | - Keiko Yanagihara
- Department of Breast Surgery and Oncology, Nippon Medical School Tama Nagayama Hospital
| | - Ryuji Ohashi
- Department of Integrated Diagnostic Pathology, Nippon Medical School
| | - Hiroyuki Takei
- Department of Breast Surgery and Oncology, Nippon Medical School Hospital
| |
Collapse
|
2
|
Kajiwara Y, Takahashi A, Ueno H, Kakeji Y, Hasegawa H, Eguchi S, Goi T, Saiura A, Sasaki A, Takiguchi S, Takeuchi H, Tanaka C, Hashimoto M, Hiki N, Horiguchi A, Matsuda S, Mizushima T, Marubashi S, Gotoh M, Konno H, Yamamoto H, Miyata H, Seto Y, Kitagawa Y, The National Clinical Database. Annual report on National Clinical Database 2020 for gastroenterological surgery in Japan. Ann Gastroenterol Surg 2023; 7:367-406. [PMID: 37152776 PMCID: PMC10154850 DOI: 10.1002/ags3.12662] [Citation(s) in RCA: 37] [Impact Index Per Article: 18.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/30/2022] [Revised: 01/16/2023] [Accepted: 01/23/2023] [Indexed: 04/04/2023] Open
Abstract
Aim The National Clinical Database (NCD) of Japan is a nationwide data entry system for surgery, and it marked its 10th anniversary in 2020. The aim was to present the 2020 annual report of gastroenterological surgery of the NCD. Methods The data of the surgical procedures stipulated by the training curriculum for board-certified surgeons of the Japanese Society of Gastroenterological Surgery in the NCD from 2011 to 2020 were summarized. Results In total, 5 622 845 cases, including 593 088 cases in 2020, were extracted from the NCD. The total number of gastroenterological surgeries increased gradually in these 10 years, except for the year 2020 due to the COVID-19 pandemic. The annual number of surgeries of each organ, except the pancreas and liver, decreased by 0.4%-13.1% in 2020 compared to 2019. The surgical patients were consistently aging, with more than 20% of all gastroenterological surgeries in 2020 involving patients aged 80 years or older. The participation of board-certified surgeons increased for each organ (75.9%-95.7% in 2020). The rates of endoscopic surgery also increased constantly. Although the incidences of postoperative complications of each organ increased by 0.7%-7.9% in these 10 years, postoperative mortality rates decreased by 0.2%-1.5%. Conclusions We present here the short-term outcomes of each gastroenterological operative procedure in 2020. This review of the 10-years of NCD data of gastroenterological surgery revealed a consistent increase of the number of surgeries (except for in 2020), especially endoscopic procedures, and aging of the Japanese population. The good safety of Japanese gastroenterological surgeries was also indicated.
Collapse
Affiliation(s)
| | - Arata Takahashi
- Department of Health Policy and Management, School of MedicineKeio UniversityTokyoJapan
- Department of Healthcare Quality Assessment Graduate School of MedicineThe University of TokyoTokyoJapan
| | - Hideki Ueno
- The Japanese Society of Gastroenterological SurgeryTokyoJapan
| | | | | | - Susumu Eguchi
- The Japanese Society of Gastroenterological SurgeryTokyoJapan
| | - Takanori Goi
- The Japanese Society of Gastroenterological SurgeryTokyoJapan
| | - Akio Saiura
- The Japanese Society of Gastroenterological SurgeryTokyoJapan
| | - Akira Sasaki
- The Japanese Society of Gastroenterological SurgeryTokyoJapan
| | - Shuji Takiguchi
- The Japanese Society of Gastroenterological SurgeryTokyoJapan
| | - Hiroya Takeuchi
- The Japanese Society of Gastroenterological SurgeryTokyoJapan
| | - Chie Tanaka
- The Japanese Society of Gastroenterological SurgeryTokyoJapan
| | | | - Naoki Hiki
- The Japanese Society of Gastroenterological SurgeryTokyoJapan
| | | | - Satoru Matsuda
- The Japanese Society of Gastroenterological SurgeryTokyoJapan
| | | | | | - Mitsukazu Gotoh
- The Japanese Society of Gastroenterological SurgeryTokyoJapan
| | - Hiroyuki Konno
- The Japanese Society of Gastroenterological SurgeryTokyoJapan
| | - Hiroyuki Yamamoto
- Department of Health Policy and Management, School of MedicineKeio UniversityTokyoJapan
- Department of Healthcare Quality Assessment Graduate School of MedicineThe University of TokyoTokyoJapan
| | - Hiroaki Miyata
- Department of Health Policy and Management, School of MedicineKeio UniversityTokyoJapan
- Department of Healthcare Quality Assessment Graduate School of MedicineThe University of TokyoTokyoJapan
| | - Yasuyuki Seto
- The Japanese Society of Gastroenterological SurgeryTokyoJapan
| | - Yuko Kitagawa
- The Japanese Society of Gastroenterological SurgeryTokyoJapan
| | | |
Collapse
|
3
|
Oguma J, Ozawa S, Sakakibara T, Kajiwara H, Nakamura N, Makuuchi H. Prognostic impact of LY6K and CDCA1 expression for patients with esophageal squamous cell carcinoma. Ann Gastroenterol Surg 2021; 5:194-203. [PMID: 33860139 PMCID: PMC8034699 DOI: 10.1002/ags3.12415] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/24/2020] [Revised: 11/18/2020] [Accepted: 11/19/2020] [Indexed: 11/06/2022] Open
Abstract
AIM In the present study, we investigated the relationship between the expressions of two cancer testis antigens (CTA), LY6K (lymphocyte antigen 6 complex locus K) and CDCA1 (cell division cycle associated 1), in esophageal squamous cell carcinoma (ESCC) tumors and the long-term outcomes of patients with ESCC to clarify the clinical significance of LY6K and CDCA1 expression in ESCC tumors. METHODS A total of 175 patients with thoracic ESCC who had undergone a thoracic esophagectomy with three-field lymphadenectomy without neoadjuvant therapy were retrospectively reviewed in this study. LY6K and CDCA1 expressions were evaluated in tumor tissues using immunohistochemical (IH) staining. RESULTS Median patient age was 63 years; 159 patients (90.9%) were men. Ninety-four patients (55.3%) were LY6K-positive, and 85 patients (48.6%) were CDCA1-positive. The LY6K-positive group had a significantly worse overall survival (OS) than the LY6K-negative group (P = 0.012), and the CDCA1-positive group had a significantly worse OS than the CDCA1-negative group (P = 0.010). A multivariate analysis suggested that pathological N stage, venous invasion, LK6Y-positive and CDCA1-positive were independent prognostic factors. The patients were classified into four groups according to the staining pattern combinations of the two CTA. The LY6K-positive and CDCA1-positive group was found to have a significantly poorer outcome than the other groups. CONCLUSION ESCC patients with a combination of LY6K and CDCA1 expression in their tumor tissues had a worse prognosis than all the other ESCC patients and it was an independent factor associated with prognosis for patients with ESCC.
Collapse
Affiliation(s)
- Junya Oguma
- Department of Gastroenterological SurgeryTokai University School of MedicineIseharaJapan
| | - Soji Ozawa
- Department of Gastroenterological SurgeryTokai University School of MedicineIseharaJapan
| | - Terue Sakakibara
- Department of Gastroenterological SurgeryTokai University School of MedicineIseharaJapan
| | - Hiroshi Kajiwara
- Department of PathologyTokai University School of MedicineIseharaJapan
| | - Naoya Nakamura
- Department of PathologyTokai University School of MedicineIseharaJapan
| | - Hiroyasu Makuuchi
- Department of Gastroenterological SurgeryTokai University School of MedicineIseharaJapan
| |
Collapse
|
4
|
IMP3 Immunohistochemical Expression in Inverted Papilloma and Inverted Papilloma-Associated Sinonasal Squamous Cell Carcinoma. ACTA ACUST UNITED AC 2021; 2021:6639834. [PMID: 33680717 PMCID: PMC7904363 DOI: 10.1155/2021/6639834] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2020] [Accepted: 02/08/2021] [Indexed: 11/17/2022]
Abstract
Sinonasal inverted papilloma (IP) has a propensity for malignant transformation. Although the IP-associated squamous cell carcinoma (SCC) is rare, it has a poor prognosis. To the best of our knowledge, this is the first study to assess IMP3 immunohistochemical (IHC) expression in sinonasal tumors and to compare it to the Ki-67 IHC expression and to other established clinicopathological parameters. A retrospective study was conducted on three groups which consisted of 72 cases of sinonasal IP, 20 age-matched samples of normal respiratory epithelium, and 15 cases of sinonasal SCC associated with IP, which were obtained from the archives of the Pathology Lab of Ain Shams University Specialized and Ain Shams University Hospitals during the period from January 2012 to December 2019. An IHC study was performed to evaluate IMP3 and Ki-67 expression in the three groups, with correlation of IMP3 expression to established clinicopathological parameters of sinonasal SCC on top of IP. Both IMP3 and Ki-67 showed a sharp rise in expression in the sinonasal SCC group. In addition, there were statistically significant differences in expression values between the 3 groups (P = 0.001). Receiver Operating Characteristic (ROC) analysis revealed that IMP3 and Ki-67 could be used to discriminate sinonasal SCC from control and IP lesions, with sensitivity and specificity of 100% and 81.5% for IMP3, respectively, and 100% and 62.5% for Ki-67, respectively. Spearman's rho revealed that both IMP3 and Ki-67 were significantly related to the lymph node and tumor stages but not to the tumor grade. ROC analysis was performed to select cut-off scores for progression and survival for IMP3, and accordingly, Kaplan-Meier analysis showed correlation between IMP3 and overall survival, local recurrence-free survival, and metastasis-free survival in sinonasal SCC cases at the selected cut-off values. Based on our results, IMP3 could serve as a promising diagnostic, prognostic, and therapeutic marker for IP-associated sinonasal SCC.
Collapse
|
5
|
Maržić D, Čoklo M, Marijić B, Hadžisejdić I, Dekanić A, Krstulja M, Šepić T, Avirović M, Braut T. The expression of ribonuclear protein IMP3 in laryngeal carcinogenesis. Pathol Res Pract 2020; 216:152974. [PMID: 32370989 DOI: 10.1016/j.prp.2020.152974] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/21/2020] [Revised: 04/11/2020] [Accepted: 04/13/2020] [Indexed: 12/15/2022]
Abstract
OBJECTIVE The aim of the study was to investigate the expression of ribonuclear protein IMP3 in laryngeal carcinogenesis, together with other biomarkers of carcinogenesis (Ki-67, p53 and cyclin D1), and to evaluate their predictive values. METHODS The study included 153 patients divided into three groups: 68 operated for primary invasive laryngeal squamous cell carcinoma (LSCC); 41 with precancerous lesions of atypical and abnormal hyperplasia; 44 with hyperplastic laryngeal nodule without atypia. Tissue microarray technique was used for immunohistochemical analysis. RESULTS All markers showed statistically significant differences between the three groups. The percentage of IMP3 positive cells is statistically significantly higher in LSCC group in comparison to precancerosis and control group. The percentage of Ki-67 positive cells is statistically significantly higher in LSCC group in comparison to precancerosis and control group. The percentage of p53 positive cells in LSCC group is statistically significantly higher than the control group and higher, but not statistically significant, than the precancerosis group. The percentage of cyclin D1 positive cells is statistically significantly higher in LSCC group than in precancerosis group and higher, but not statistically significant, than in the control group. All analyzed markers have good predictive values (AUC > 0.6), but the percentage of IMP3 positive cells is the only statistically significant marker in predicting whether the patient has LSCC or not. CONCLUSION Expression of Ki-67 and pronouncedly IMP3 generally follow the same pattern where control and precancerosis are similar and LSCC significantly differs, as opposed to p53 and cyclin D1. IMP3 expression increase possibly has an important diagnostic, therapeutic (in terms of the need for additional therapy after surgery) and prognostic value. Further studies on the exact molecular mechanisms behind it are, of course, needed.
Collapse
Affiliation(s)
- Diana Maržić
- Department of Audiology and Phoniatrics, Clinical Hospital Centre Rijeka, Rijeka, Croatia; Department of Otorhinolaryngology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia
| | - Miran Čoklo
- Centre for Applied Bioanthropology, Institute for Anthropological Research, Zagreb, Croatia
| | - Blažen Marijić
- Department of Otorhinolaryngology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia; Clinic for Otorhinolaryngology and Head and Neck Surgery, Clinical Hospital Centre Rijeka, Rijeka, Croatia
| | - Ita Hadžisejdić
- Department of Pathology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia; Clinical Department of Pathology and Cytology, Clinical Hospital Center Rijeka, Rijeka, Croatia
| | - Andrea Dekanić
- Department of Pathology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia
| | - Mira Krstulja
- Department of Pathology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia
| | - Tatjana Šepić
- Department of Audiology and Phoniatrics, Clinical Hospital Centre Rijeka, Rijeka, Croatia; Department of Otorhinolaryngology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia
| | - Manuela Avirović
- Department of Pathology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia
| | - Tamara Braut
- Department of Otorhinolaryngology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia; Clinic for Otorhinolaryngology and Head and Neck Surgery, Clinical Hospital Centre Rijeka, Rijeka, Croatia.
| |
Collapse
|